Personal Health Care Spending Continues to Soar in the U.S.

Share this content:
Personal Health Care Spending Continues to Soar in the U.S.
Personal Health Care Spending Continues to Soar in the U.S.

TUESDAY, Dec. 27, 2016 (HealthDay News) -- From 1996 to 2013 there were considerable increases in personal health care spending in the United States, with the highest amounts for diabetes, ischemic heart disease, and low back and neck pain, according to a study published in the Dec. 27 issue of the Journal of the American Medical Association.

Joseph L. Dieleman, Ph.D., from the Institute for Health Metrics and Evaluation in Seattle, and colleagues estimated U.S. spending on personal health care and public health using data from government budgets, insurance claims, facility surveys, household surveys, and official U.S. records from 1996 to 2013. A total of 183 data sources were used to estimate spending for 155 conditions.

The researchers found that $30.1 trillion of personal health care spending was disaggregated by 155 conditions, age and sex group, and type of care from 1996 to 2013. Diabetes had the highest health care spending in 2013, with an estimated $101.4 billion in spending, including 57.6 and 23.5 percent spent on pharmaceuticals and ambulatory care, respectively. The second- and third-highest amount of health care spending was on ischemic heart disease and low back and neck pain, with estimated health care spending of $88.1 and $87.6 billion, respectively. From 1996 to 2013, personal health care spending increased for 143 of 155 conditions; over the study period, spending on low back and neck pain and diabetes increased the most.

"This information may have implications for efforts to control U.S. health care spending," the authors write.

Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »